StockData
Protagenic Therapeutics, Inc.new logo

Protagenic Therapeutics, Inc.new (PTIX) stock

PTIXOTCPharmaceutical PreparationsFiscal year ends March 31
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026
$0.75+0.00 (0.00%)

Close on Oct 19, 2026Market cap $1.36MP/E –Yield –

Protagenic Therapeutics, Inc.new operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Protagenic Therapeutics, Inc.new's operating income for the twelve months ending Dec 31, 2024 was -$5.70M. For fiscal 2024 it was -$5.70M. The highest annual figure on record is -$2.09M in fiscal 2019.

Annual operating income

PeriodPeriod endValueChange
FY2024Dec 31, 2024-$5.70M–
FY2023Dec 31, 2023-$4.53M–
FY2022Dec 31, 2022-$3.56M–
FY2021Dec 31, 2021-$4.14M–
FY2020Dec 31, 2020-$2.55M–
FY2019Dec 31, 2019-$2.09M–
FY2018Dec 31, 2018-$2.31M–
FY2017Dec 31, 2017-$2.37M–
FY2016Dec 31, 2016-$2.23M–

Quarterly operating income

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q1 FY2027CQ1 2026Jun 30, 2026-$961.25K–
Q4 FY2024CQ4 2024Dec 31, 2024-$401.40K–
Q3 FY2024CQ3 2024Sep 30, 2024-$355.37K–
Q2 FY2024CQ2 2024Jun 30, 2024-$321.83K–
Q1 FY2024CQ1 2024Mar 31, 2024-$1.74M–
Q4 FY2023CQ4 2023Dec 31, 2023-$1.21M–
Q3 FY2023CQ3 2023Sep 30, 2023-$1.43M–
Q2 FY2023CQ2 2023Jun 30, 2023-$1.14M–
Q1 FY2023CQ1 2023Mar 31, 2023-$739.29K–
Q4 FY2022CQ4 2022Dec 31, 2022-$655.78K–
Q3 FY2022CQ3 2022Sep 30, 2022-$924.06K–
Q2 FY2022CQ2 2022Jun 30, 2022-$636.67K–
Q1 FY2022CQ1 2022Mar 31, 2022-$1.34M–
Q4 FY2021CQ4 2021Dec 31, 2021-$861.22K–
Q3 FY2021CQ3 2021Sep 30, 2021-$764.17K–
Q2 FY2021CQ2 2021Jun 30, 2021-$1.31M–
Q1 FY2021CQ1 2021Mar 31, 2021-$1.21M–
Q4 FY2020CQ4 2020Dec 31, 2020-$536.88K–
Q3 FY2020CQ3 2020Sep 30, 2020-$1.09M–
Q2 FY2020CQ2 2020Jun 30, 2020-$488.94K–
Q1 FY2020CQ1 2020Mar 31, 2020-$520.74K–
Q4 FY2019CQ4 2019Dec 31, 2019-$737.23K–
Q3 FY2019CQ3 2019Sep 30, 2019-$189.62K–
Q2 FY2019CQ2 2019Jun 30, 2019-$505.26K–
Q1 FY2019CQ1 2019Mar 31, 2019-$654.02K–
Q4 FY2018CQ4 2018Dec 31, 2018-$524.25K–
Q3 FY2018CQ3 2018Sep 30, 2018-$498.07K–
Q2 FY2018CQ2 2018Jun 30, 2018-$685.13K–
Q1 FY2018CQ1 2018Mar 31, 2018-$606.68K–
Q4 FY2017CQ4 2017Dec 31, 2017-$708.78K–
Q3 FY2017CQ3 2017Sep 30, 2017-$527.03K–
Q2 FY2017CQ2 2017Jun 30, 2017-$471.59K–
Q1 FY2017CQ1 2017Mar 31, 2017-$657.92K–
Q4 FY2016CQ4 2016Dec 31, 2016-$556.28K–
Q3 FY2016CQ3 2016Sep 30, 2016-$454.83K–
Q2 FY2016CQ2 2016Jun 30, 2016-$496.66K–
Q1 FY2016CQ1 2016Mar 31, 2016-$725.74K–
Q3 FY2014CQ1 2014Mar 31, 2014-$398.00K–
Q2 FY2014CQ4 2013Dec 31, 2013-$242.00K–

More Protagenic Therapeutics, Inc.new figures

See a number that looks wrong?